Case | Age/ Sex | Type of NHL and stage at diagnosis | Time (months) from diagnosis to hypercalcaemia | Highest calcium value (mmol/l) | Recurrence of hypercalcaemia | Treatment | Response | Survival (months) from developing hypercalcaemia |
---|---|---|---|---|---|---|---|---|
Normal calcium range, 2.2–2.6 mmol/l. Type of B-NHL: DLBC, diffuse large B cell; HGGM, high grade gastric maltoma; FCC, follicular centre cell. Chemotherapy protocols: C, cyclophosphamide; I, idarubicin; D, dexamethasone, E, etoposide; B, bleomycine; O, vincristine; M, methotrexate in BOM, melphalan in mini-BEAM; H, doxorubicin; P, prednisolone; A, ARA-C; DXR, radiotherapy. Response: CR, complete response; NR, no response; PR, partial response. | ||||||||
1 | 51/M | DLB | At diagnosis | 3.08 | Recurred terminally | CIDEBOM | NR | 11 |
IIIB | DXR | NR | ||||||
2 | 23/M | DLBC | At diagnosis | 4.05 | No recurrence | CHOP | PR, early relapse | 10 |
IVB | ||||||||
3 | 71/F | HGGM | At diagnosis | 4.16 | Recurrent | CHOP | PR | 10 |
IVB | DXR | NR | ||||||
4 | 70/F | DLBC | At diagnosis | 2.96 | No recurrence | CIOP | NR | 9 |
IIIB | Mini-BEAM | PR | ||||||
5 | 61/F | HGGM | At diagnosis | 2.92 | No recurrence | CIOP | PR | 9 |
IVB | ||||||||
6 | 57/M | DLBC | 24, at relapse | 3.16 | Recurred terminally | CIOP | CR | 5 |
IIIB | Mini-BEAM | PR | ||||||
IVB at relapse | ||||||||
7 | 65/F | FCC | 49, at the time of transformation | 3.02 | No response to treatment | Chlorambucil | PR | 2 |
IVB | Mini-BEAM | NR | ||||||
DLBC at transformation | ||||||||
8 | 74/M | FCC | 15, at relapse | 3.27 | Recurred terminally | Chlorambucil | PR | 9 |
IVA | CHOP | PR |